CO5690585A2 - Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor - Google Patents
Uso de inhibidores de la ikb-quinasa para el tratamiento del dolorInfo
- Publication number
- CO5690585A2 CO5690585A2 CO05013333A CO05013333A CO5690585A2 CO 5690585 A2 CO5690585 A2 CO 5690585A2 CO 05013333 A CO05013333 A CO 05013333A CO 05013333 A CO05013333 A CO 05013333A CO 5690585 A2 CO5690585 A2 CO 5690585A2
- Authority
- CO
- Colombia
- Prior art keywords
- unsubstituted
- substituted
- heterocycle
- heteroaryl
- aryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Paper (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Uso de inhibidores de la I?B-quinasa para producir fármacos para tratar dolores.2.- Uso del compuesto de la fórmula I y/o una forma estereoisomérica del compuesto de la fórmula I y/o una sal fisiológicamente tolerada del compuesto de la fórmula I, para producir fármacos para tratar dolores, donde E es un átomo de N o el radical -C(R19)-, donde R19 es un átomo de hidrógeno o el radical R9, uno de los sustituyentes R1, R2, R3 y R4 es un radical de la fórmula II,en la que D es -C(O)-, S(O)- o -S(O)2R8 es un átomo de hidrógeno o alquilo-(C1-C4)-, R9 es 1. un radical característico de aminoácido, 2. arilo, en el cual el arilo está sustituido o insustituido, 3. heteroarilo con de 5 a 14 anillos, en el cual el heteroarilo es sustituido o insustituido, 4. un heterociclo con de 5 a 12 anillos, en el cual el heterociclo es sustituido o insustituido, 5. alquilo-(C1-C6)-, en el que el alquilo es lineal o ramificado y está sustituido o insustituido, una dos o tres veces, independientemente uno de otro, por 5.1 arilo, en el que el arilo está insustituido o sustituido, 5.2 heteroarilo, con 5-14 anillos, en el que el heteroarilo está insustituido o sustituido, 5.3 un heterociclo con 5-12 anillos, en el que el heterociclo está insustituido o sustituido, 5.4 - O-R11, 5.5 = O, 5.6 halógeno, 5.7 -CN, 5.8 -CF3, ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10237723A DE10237723A1 (de) | 2002-08-17 | 2002-08-17 | Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5690585A2 true CO5690585A2 (es) | 2006-10-31 |
Family
ID=31968975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05013333A CO5690585A2 (es) | 2002-08-17 | 2005-02-15 | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1531819B1 (es) |
| JP (1) | JP4504811B2 (es) |
| KR (2) | KR20110135428A (es) |
| CN (1) | CN100398107C (es) |
| AR (1) | AR043045A1 (es) |
| AT (1) | ATE418336T1 (es) |
| AU (1) | AU2003271555B2 (es) |
| BR (1) | BR0313555A (es) |
| CA (1) | CA2495455C (es) |
| CO (1) | CO5690585A2 (es) |
| CR (1) | CR7716A (es) |
| CY (1) | CY1108874T1 (es) |
| DE (2) | DE10237723A1 (es) |
| DK (1) | DK1531819T3 (es) |
| EC (1) | ECSP055609A (es) |
| ES (1) | ES2320118T3 (es) |
| HK (1) | HK1079426A1 (es) |
| HR (1) | HRP20050041B1 (es) |
| IL (1) | IL166780A (es) |
| MA (1) | MA27334A1 (es) |
| MX (1) | MXPA05001218A (es) |
| MY (1) | MY138059A (es) |
| NO (1) | NO334309B1 (es) |
| OA (1) | OA12907A (es) |
| PL (1) | PL212356B1 (es) |
| PT (1) | PT1531819E (es) |
| RS (1) | RS51878B (es) |
| RU (1) | RU2320338C2 (es) |
| SI (1) | SI1531819T1 (es) |
| TN (1) | TNSN05044A1 (es) |
| TW (1) | TWI325782B (es) |
| UA (1) | UA80837C2 (es) |
| WO (1) | WO2004022057A1 (es) |
| ZA (1) | ZA200500323B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| BRPI0511834A (pt) | 2004-07-14 | 2008-01-08 | Ptc Therapeutics Inc | métodos por tratar hepatite c |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006019832A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
| DE102005025225A1 (de) * | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| JP5790440B2 (ja) * | 2010-12-01 | 2015-10-07 | 住友化学株式会社 | ピリミジン化合物およびその有害生物防除用途 |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2532755A1 (en) * | 2011-06-10 | 2012-12-12 | Sanofi-Aventis | Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104105483B (zh) * | 2011-12-06 | 2017-03-22 | 赛诺菲 | 2‑(2‑甲基氨基‑嘧啶‑4‑基)‑1h‑吲哚‑5‑羧酸[(s)‑1‑氨甲酰基‑2‑(苯基‑嘧啶‑2‑基‑氨基)‑乙基]‑酰胺的晶体形式 |
| EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| US9968605B2 (en) * | 2014-07-03 | 2018-05-15 | Sanofi | 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis |
| KR20210032950A (ko) | 2018-07-16 | 2021-03-25 | 노파르티스 아게 | 페닐피페리디닐 인돌 유도체를 제조하기 위한 화학적 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU769350B2 (en) * | 1999-06-23 | 2004-01-22 | Sanofi-Aventis Deutschland Gmbh | Substituted benzimidazole |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
-
2002
- 2002-08-17 DE DE10237723A patent/DE10237723A1/de not_active Withdrawn
-
2003
- 2003-05-08 UA UAA200502388A patent/UA80837C2/uk unknown
- 2003-08-05 PL PL373568A patent/PL212356B1/pl unknown
- 2003-08-05 BR BR0313555-1A patent/BR0313555A/pt not_active Application Discontinuation
- 2003-08-05 OA OA1200500046A patent/OA12907A/en unknown
- 2003-08-05 KR KR1020117028345A patent/KR20110135428A/ko not_active Application Discontinuation
- 2003-08-05 AT AT03753349T patent/ATE418336T1/de active
- 2003-08-05 KR KR1020057002712A patent/KR101119845B1/ko not_active IP Right Cessation
- 2003-08-05 JP JP2004533318A patent/JP4504811B2/ja not_active Expired - Fee Related
- 2003-08-05 DK DK03753349T patent/DK1531819T3/da active
- 2003-08-05 SI SI200331531T patent/SI1531819T1/sl unknown
- 2003-08-05 WO PCT/EP2003/008628 patent/WO2004022057A1/de active Application Filing
- 2003-08-05 PT PT03753349T patent/PT1531819E/pt unknown
- 2003-08-05 DE DE50310980T patent/DE50310980D1/de not_active Expired - Lifetime
- 2003-08-05 RS YU20050070A patent/RS51878B/sr unknown
- 2003-08-05 AU AU2003271555A patent/AU2003271555B2/en not_active Ceased
- 2003-08-05 MX MXPA05001218A patent/MXPA05001218A/es active IP Right Grant
- 2003-08-05 RU RU2005107419/15A patent/RU2320338C2/ru not_active IP Right Cessation
- 2003-08-05 CN CNB038195429A patent/CN100398107C/zh not_active Expired - Fee Related
- 2003-08-05 CA CA2495455A patent/CA2495455C/en not_active Expired - Fee Related
- 2003-08-05 EP EP03753349A patent/EP1531819B1/de not_active Expired - Lifetime
- 2003-08-05 ES ES03753349T patent/ES2320118T3/es not_active Expired - Lifetime
- 2003-08-14 TW TW092122310A patent/TWI325782B/zh not_active IP Right Cessation
- 2003-08-14 AR ARP030102944A patent/AR043045A1/es not_active Application Discontinuation
- 2003-08-15 MY MYPI20033112A patent/MY138059A/en unknown
-
2005
- 2005-01-13 ZA ZA200500323A patent/ZA200500323B/xx unknown
- 2005-01-14 HR HRP20050041AA patent/HRP20050041B1/hr not_active IP Right Cessation
- 2005-02-09 IL IL166780A patent/IL166780A/en not_active IP Right Cessation
- 2005-02-15 MA MA28107A patent/MA27334A1/fr unknown
- 2005-02-15 CO CO05013333A patent/CO5690585A2/es not_active Application Discontinuation
- 2005-02-16 TN TNP2005000044A patent/TNSN05044A1/en unknown
- 2005-02-17 EC EC2005005609A patent/ECSP055609A/es unknown
- 2005-03-07 CR CR7716A patent/CR7716A/es unknown
- 2005-03-15 NO NO20051339A patent/NO334309B1/no not_active IP Right Cessation
- 2005-12-12 HK HK05111381.9A patent/HK1079426A1/xx not_active IP Right Cessation
-
2009
- 2009-03-17 CY CY20091100291T patent/CY1108874T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5690585A2 (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
| CY1115533T1 (el) | Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr | |
| CY1112377T1 (el) | Μεθοδος και συνθεσεις για τη θεραπευτικη aντιμετωπιση των αιματολογικων κακοηθειων | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| NO20054340L (no) | Nye sammenkoplede heterocykler og deres anvendelse | |
| NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
| CY1110498T1 (el) | Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα | |
| AR044650A1 (es) | Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa. | |
| ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
| NO20080963L (no) | Piperidinyl-substiuerte isokinolinderivater som Rho-kinaseinhibitorer | |
| GT200600398A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
| CY1111843T1 (el) | 2-υποκατεστημενα αναλογα βιταμινης d και θεραπευτικες χρησεις αυτων | |
| CY1110392T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
| ATE523486T1 (de) | Pleuromutilinderivate zur behandlung von durch mikroben vermittelten krankheiten | |
| CY1112706T1 (el) | Παραγωγα 4-βενζυλαμινο-1-καρβοξυακυλ-πιπεριδινης ως αναστολεις της cετρ, χρησιμοι για τη θεραπεια ασθενειων οπως η υπερλιπιδαιμια ή η αρτήριοσκληρωση | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| CY1109085T1 (el) | Νεα αλατα | |
| AR050250A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica | |
| AR053453A1 (es) | Derivados de aminoalquil- y amidoalquil-benzopirano substituidos | |
| UY27716A1 (es) | Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo. | |
| NO303175B1 (no) | Geneserinderivater som kolinesterase-hemmere | |
| CY1105786T1 (el) | Εκδοχα φλαβονων η διαδικασια παρασκευης τους, η εφαρμογη τους ως φαρμακα | |
| PE20040750A1 (es) | Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3 | |
| CO5540388A2 (es) | Nuevas arisulfonamidas como agentes antivirales | |
| NO20054721L (no) | Substituerte anilinderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |